TITLE

On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort

AUTHOR(S)
Cortese, D; Sutton, L-A; Cahill, N; Smedby, K E; Geisler, C; Gunnarsson, R; Juliusson, G; Mansouri, L; Rosenquist, R
PUB. DATE
March 2014
SOURCE
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p710
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a multivariate analysis of overall survival (OS) based on the mutational status of SF3B1, NOTCH1, BIRC3 and TP53 genes. The finding shows that the BIRC3 mutation frequency is low at diagnosis, but that mutations might emerge and evolve, specially in patients having relapsing/refractory chronic lymphocytic leukemia (CLL). It reveals that 9.2% of the examined cases harbored big deletions in chromosome 11, which frequently encompassed the whole BIRC3 gene with other genes.
ACCESSION #
94762952

 

Related Articles

  • Unraveling the Molecular Pathogenesis of Chronic Lymphocytic Leukemia: Dissecting a MicroRNA Regulatory Network. Allendorf, Daniel J.; Davis, Randall S. // JAMA: Journal of the American Medical Association;1/5/2011, Vol. 305 Issue 1, p95 

    The authors examine the results of studies on the pathogenesis of B-cell chronic lymphocytic leukemia (CLL). They report the prevalence of this type of leukemia in Western countries, with an annual incidence of 4.2 per 100,000. They explore a study by D. C. Corney et al on the potential of tumor...

  • Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Thornton, Patrick D.; Gruszka-Westwood, Alicja M.; Hamoudi, Rifat A.; Atkinson, Shayne; Kaczmarek, Pawel; Morilla, Ricardo M.; Hilditch, Benjamin L.; A'Hern, Roger; Matutes, Estella; Catovsky, Daniel // Hematology Journal;2004, Vol. 5 Issue 1, p47 

    Abnormalities of TP53 in chronic lymphocytic leukaemia (CLL) correlate with aggressive disease and transformation. We studied 115 patients with CLL including 90 untreated, 25 with heavily pretreated/refractory CLL using fluorescent in situ hybridisation (FISH) to detect allelic loss at...

  • Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Cortelezzi, A; Sciumè, M; Liberati, A M; Vincenti, D; Cuneo, A; Reda, G; Laurenti, L; Zaja, F; Marasca, R; Chiarenza, A; Gritti, G; Orsucci, L; Storti, S; Angelucci, E; Cascavilla, N; Gobbi, M; Mauro, F R; Morabito, F; Fabris, S; Piciocchi, A // Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p642 

    We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of bendamustine in combination with ofatumumab (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL)....

  • Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity. Zauli, G.; Di Iasio, M. G.; Secchiero, P.; Dal Bo, M.; Marconi, D.; Bomben, R.; Del Poeta, G.; Gattei, V. // Current Cancer Drug Targets;Jun2009, Vol. 9 Issue 4, p510 

    By analyzing the cDNA obtained from 16 B-cell chronic lymphocytic leukemia (B-CLL) patient samples, we found that Nutlin-3, a small molecule inhibitor of MDM2/p53 interaction, induced a characteristic gene expression profile (GEP) signature in 13 out of 16 B-CLL samples. The lack of...

  • Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL. Halina, Antosz; Artur, Paterski; Barbara, Marzec-Kotarska; Joanna, Sajewicz; Anna, Dmoszyńska // Folia Histochemica et Cytobiologica;2010, Vol. 48 Issue 4, p534 

    B-cell chronic lymphocytic leukaemia (B-CLL) originates from B lymphocytes that may differ in the activation level, maturation state or cellular subgroups in peripheral blood. Tumour progression in CLL B cells seems to result in gradual accumulation of the clone of resting B lymphocytes in the...

  • Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Fox, Christopher // Current Medical Literature: Leukemia & Lymphoma;2014, Vol. 22 Issue 2, p46 

    The article discusses a study published in the journal "Blood" which evaluated mutations of tumor protein p53 (TP53) gene in chronic lymphocytic leukemia (CLL) patients. Topics include clinical insight on TP53 mutation as an accurate indicator of CLL prognosis, the application of next-generation...

  • Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53) Deletion in Chronic Lymphocytic Leukemia. Hong Chang // American Journal of Clinical Pathology;Jan2010, Vol. 133 Issue 1, p70 

    Hemizygous TP53 gene deletion is the most important adverse risk factor in chronic lymphocytic leukemia (CLL), but its relationship with p53 protein expression is unclear. We investigated 110 CLL cases and correlated nuclear p53 protein immunoreactivity with TP53 gene deletion status and other...

  • Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Bevan, S; Catovsky, D; Marossy, A; Matutes, E; Popat, S; Antonovic, P; Bell, A; Berrebi, A; Gaminara, E J; Quabeck, K; Ribeiro, I; Mauro, F R; Stark, P; Sykes, H; van Dongen, J; Wimperis, J; Wright, S; Yuille, M R; Houlston, R S; Gaminara, E // Leukemia (08876924);Oct99, Vol. 13 Issue 10, p1497 

    B cell chronic lymphocytic leukaemia (CLL) shows evidence of familial aggregation, but the inherited basis is poorly understood. Mutations in the ATM gene have been demonstrated in CLL. This, coupled with a possibly increased risk of leukaemia in relatives of patients with Ataxia Telangiectasia,...

  • Polymorphisms in Thioredoxin Reductase and Selenoprotein K Genes and Selenium Status Modulate Risk of Prostate Cancer. Méplan, Catherine; Rohrmann, Sabine; Steinbrecher, Astrid; Schomburg, Lutz; Jansen, Eugène; Linseisen, Jakob; Hesketh, John // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Increased dietary intake of Selenium (Se) has been suggested to lower prostate cancer mortality, but supplementation trials have produced conflicting results. Se is incorporated into 25 selenoproteins. The aim of this work was to assess whether risk of prostate cancer is affected by genetic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics